Skip to main content
Premium Trial:

Request an Annual Quote

Allen Roses Dies

Allen Roses, a professor of neurobiology at Duke University School of Medicine, has died. He was 73.

Roses is known for his contribution to Alzheimer's disease research, the News and Observer reports. While at Duke in the 1990s, he and his team linked the disease to the APOE gene, a finding that was met with skepticism, the paper notes.

"He wasn't shy about standing up to his critics," Kathleen Welsh-Bohmer, the director of the Bryan Alzheimer's Disease Research Center at Duke, tells the News and Observer. "He was fearless."

In 2009, Roses and his team linked another gene, TOMM40, to Alzheimer's. Zinfandel Pharmaceuticals — a company started by Roses that same year — is working with Takeda on a phase III clinical trial to gauge whether TOMM40 can act as a biomarker for disease risk and if the diabetes drug Actos can delay disease onset.

Prior to re-joining Duke in 2008, Roses was a senior vice president at GlaxoSmithKline, where he led its genetics research and pharmacogenetics section. He also founded Cabernet Pharmaceuticals that year to offer pharmacogenetics and project-management services to pharma, biotech, and academic groups.

More recently, Roses implicated a simple sequence repeat in Lou Gehrig's disease, or amyotrophic lateral sclerosis. He told GenomeWeb last month that his team developed a database of short structural variants, which they used to identify a simple polyT sequence repeat near an ALS-linked gene.

GenomeWeb's Turna Ray notes that Roses' work — such as his ApoE and TOMM40 findings — has often been controversial. And his recent focus on short structural variants was trying to spur the field to move beyond genome-wide association studies.

"He treated every day like it was his last one because he knew it probably was," Stephanie Roses, his daughter, tells the News-Observer. Roses had suffered two heart attacks prior to the fatal one last Friday. "He lived that way for the last 26 years," she adds.

Even until recently, "he was still doing everything at 100 miles per hour," she says.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.